

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

INSIDE INFORMATION THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated May 29, 2024 in relation to the issuance of Filing Notice by CSRC regarding the implementation of the H share full circulation of the Company (the “**Announcement**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

The Company has applied to the Listing Committee of the Stock Exchange for the approval of the listing of and permission to deal in 120,463,260 H Shares (the “**Converted H Shares**”) on the Main Board of the Stock Exchange (the “**Conversion and Listing**”), representing the maximum number of the Unlisted Shares entitled to be converted according to the Filing Notice. The Company is pleased to announce that the listing approval was granted by the Stock Exchange on September 3, 2024 (the “**Listing Approval**”).

SHAREHOLDING STRUCTURE

The Conversion and Listing will involve a total of 11 participating shareholders (the “**Participating Shareholders**”) of 120,463,260 Unlisted Shares to be converted, who will, after the Conversion and Listing, hold approximately 34.52% of the total issued H Shares. Set out below is the percentage holding of the Participating Shareholders upon completion of the Conversion and Listing.

No.	Name of the Participating Shareholders	Number of Converted H Shares	Approximate percentage of total issued H Shares upon completion of the Conversion and Listing
1.	Dr. Tian Wenzhi (田文志)	35,091,495	10.05%
2.	Shanghai Zhangjiang Leading Initiating Venture Capital (Limited Partnership) (上海張科領弋升帆創業投資中心(有限合夥))	25,750,000	7.38%
3.	Beijing Lapam Healthcare Investment Centre (Limited Partnership) (北京龍磐健康醫療投資中心(有限合夥))	19,263,240	5.52%
4.	Jiaxing Changxian Enterprise Management L.P. (Limited Partnership) (嘉興昶咸企業管理合夥企業(有限合夥))	7,758,630	2.22%
5.	Jiaxing Changyu Enterprise Management L.P. (Limited Partnership) (嘉興昶宇企業管理合夥企業(有限合夥))	7,419,847	2.13%
6.	Suzhou Likang Equity Investment Centre (Limited Partnership) (蘇州禮康股權投資中心(有限合夥))	7,214,085	2.07%
7.	Shanghai Zhangjiang Science & Technology Venture Capital Co., Ltd. (上海張江科技創業投資有限公司)	10,862,055	3.11%
8.	Granite Peak Limited	2,271,082	0.65%
9.	Ningbo Yaluo Venture Capital Partnership (Limited Partnership) (寧波雅羅創業投資合夥企業(有限合夥)) (formerly known as Shihezi Yaluo Equity Investment Partnership (Limited Partnership) (石河子市雅羅股權投資有限合夥企業))	2,347,150	0.67%
10.	Borah Peak Limited	1,731,836	0.50%
11.	Suzhou Lirun Equity Investment Centre (Limited Partnership) (蘇州禮潤股權投資中心(有限合夥))	753,840	0.22%
	Total	<u>120,463,260</u>	<u>34.52%</u>

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is set out below:

Description of Shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	<i>Number of Shares</i>	<i>Approximate percentage</i>	<i>Number of Shares</i>	<i>Approximate percentage</i>
Unlisted Shares	145,607,656	38.92%	25,144,396	6.72%
H Shares	228,550,039	61.08%	349,013,299	93.28%
Total	<u>374,157,695</u>	<u>100.00%</u>	<u>374,157,695</u>	<u>100.00%</u>

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and Listing in compliance with the requirements under the Listing Rules and the applicable laws, as and when appropriate.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Hong Kong, September 3, 2024

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.